Re-Engineering a Proven Hormone Through Modern Science
Advancing Next-Generation Hormone Science through Precision Design
Aviva Bio is a clinical-stage biotechnology company focused on rewriting the narrative around hormone-based medicine. We aim to unlock the full potential of hormone-based medicine through precision drug design for a wide range of patient populations with significant unmet needs.
The risks associated with the aromatization of testosterone have historically limited its clinical use. Aviva Bio’s lead therapeutic, AVA-291 (d3-T) is a next-generation testosterone designed to retain T’s androgen activity while resisting aromatization.
Vision
Unlocking the full potential of hormone-based medicine to transform health and well-being.
Mission
We challenge the status quo in medicine by modernizing established science, reimagining the role of hormones, and breaking barriers. Through innovative drug design, we create therapeutics that leverage small changes to make powerful, unexpected, and significant breakthroughs.
d3-T: Testosterone Re-engineered to Minimize Aromatization
The Problem
The aromatization of ordinary testosterone has been associated with clinically meaningful safety and tolerability concerns. The aromatization of T locally in breast tissue is linked to the development of gynecomastia in men and an increased risk of breast cancer in women.
The Gap
Testosterone is a well-characterized hormone that plays a critical role in libido, muscle mass, energy, metabolic health, and overall quality of life in both men and women. However, safety and tolerability risks driven by aromatization of ordinary testosterone have historically constrained its clinical use and limited the development of testosterone therapies.
Our Solution
d3-T is an investigational, next-generation testosterone designed to retain T’s androgen activity while resisting aromatization. d3-T is a differentiated androgen being developed for use in clinical situations where the aromatization of T limits its therapeutic potential in both men and women.
How d3-T Works
d3-T is an investigational next-generation testosterone designed to unlock the full potential of androgens
d3-T is being developed to explore a differentiated approach to androgen therapy. d3-T is a novel, structurally identical form of testosterone where select hydrogen molecules have been substituted with deuterium, a naturally occurring molecule in nature.
Be Part of the Breakthrough
d3-T (AVA-291) is considered a new chemical entity and is well protected by U.S. patents. We’re raising capital to take d3-T into clinical studies to achieve Phase III-ready status. If you believe in the potential of hormone-based medicine, let’s connect.
The Team Behind the Transformation
Our leadership team combines decades of pharmaceutical innovation with a bold, patient-centered vision.
The Executive Team
Our executive team combines deep expertise across pharmaceutical development, commercialization, health equity, and regulatory strategy. Together, they are committed to driving groundbreaking solutions with scientific excellence, strategic vision, and a focus on impact.
The Scientific Advisors
Guided by Pioneers in Hormone Science
Aviva’s scientific board includes world-renowned experts in endocrinology, gynecology, and hormone therapeutics.
Robert Dudley, PhD
- Former CEO Clarus Therapeutics
- Developer of Androgel and Jatenzo
- Visit his LinkedIn
Barbara Levy MD, FACOG, FACS, MSCP
- Clinical Professor, Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences
- Voluntary Clinical Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Diego Health Sciences
- Chief Medical Officer, Visana Health Inc.
- Visit her LinkedIn
Sheryl Kingsberg, PhD
- Chief, Division of Behavioral Medicine, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center
- Professor, Departments of Reproductive Biology, Psychiatry and Urology, Case Western Reserve University School of Medicine
- Clinical Psychologist specializing in female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility
- Past President: The Menopause Society and International Society for the Study of Women’s Sexual Health
- Advocacy Committee Chair: The Menopause Society
- Visit her LinkedIn
